Module No:306, 3 rd Floor, Phase2, Ticel Bio Park, Taramani, Chennai - 600 113| www.saksinlife.com Module No:306, 3 rd Floor, Phase2, Ticel Bio Park, Taramani, Chennai - 600 113| www.saksinlife.com Dr. CN Ramchand CEO, Saksin lifesciences Pvt. Ltd Chennai & San Francisco
37
Embed
Module No:306, 3 rd Floor, Phase2, Ticel Bio Park, Taramani, Chennai - 600 113| Dr. CN Ramchand CEO, Saksin lifesciences Pvt. Ltd Chennai.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Module No:306, 3rd Floor, Phase2, Ticel Bio Park, Taramani, Chennai - 600 113| www.saksinlife.com
Module No:306, 3rd Floor, Phase2, Ticel Bio Park, Taramani, Chennai - 600 113| www.saksinlife.com
Dr. CN RamchandCEO,
Saksin lifesciences Pvt. Ltd
Chennai & San Francisco
Module No:306, 3rd Floor, Phase2, Ticel Bio Park, Taramani, Chennai - 600 113| www.saksinlife.com 2
My experien
ces
Funding and development of biotech start-
upsOverview-India
& in Kerala
General outline
Vice President & Head of New Drug Discovery
Director & World Wide executive member
Chief Scientific Officer
President and CEO
President & CEO Advisor Advisor
Education
Early days
Semi-
Entrepreneur
Entrepreneur
Scientific publications= > 150
Patents => 60Conferences organized => 8
Nanoparticles for biological applications
Curcumin based products The Fish oil story
Value added basic research
Module No:306, 3rd Floor, Phase2, Ticel Bio Park, Taramani, Chennai - 600 113| www.saksinlife.com 5
Major players in the country
Advantage IndiaSkilled manpower
Large consumer base
Government funding/Venture funding
Good IT support
English proficiency Raw materials aplenty
Ancient knowledge
Ecological /Cultural diversity Agricultural base strong
Indian biotech in global contextLeadership vacuum
Publications and Patents still less
Research in Industry not significant yet
No dialogue between academics and industries
Less number of startups
Academia not ready to take risk for a venture
Less number of R&D Institutes & Universities
Shortage on mentors, advisors
Lack of awareness about opportunities
One mentionable pointUniversity’s role in supporting Innovation & Entrepreneurship
Spun off from Oxford University in 1993
Spun off from Oxford University in 1959
Spun off from Cavendish Laboratory at
the University of Cambridge in 2000
Spun off from Carnegie Mellon
University in 1994
Country Period No. Spinouts
US 1980-2003
4543
Canada 1962-2003
1100
France 1984-2005
1230
Netherlands 1980-1990s
300
Australia 1984-1999
97
UK 1981-2003
1650
Columbia University- >100 spin offs
Roadmap to success
Learning by example
Module No:306, 3rd Floor, Phase2, Ticel Bio Park, Taramani, Chennai - 600 113| www.saksinlife.com 15
Reverse pharmacology
Conventional drug discovery
Associated issues
Strategy
Curcumin
Capsaicin
6-Gingerol
Lycopene
Resvertrol
Diallyl sulphide
Indole-3-carbinol
Source SourceActive Phytochemical Active PhytochemicalApplication Application